Treatment of Chilblains (Pernio)
For idiopathic chilblains, cold avoidance and protective measures are first-line management, with oral nifedipine (typically 20 mg three times daily) as the most evidence-based pharmacologic option for severe or refractory cases, though its effectiveness remains inconsistent across studies. 1, 2
Initial Management: Non-Pharmacologic Measures
Cold protection is the cornerstone of treatment and prevention:
- Avoid cold exposure and keep extremities warm with appropriate clothing (gloves, warm socks, insulated footwear) 1, 3
- Gradual rewarming is essential—never rewarm extremities suddenly after cold exposure, as rapid warming causes vasospasm and worsens the condition 4
- Smoking cessation is strongly recommended, as smoking exacerbates vasospasm 1
- Clean and dry the affected limb thoroughly 3
Common pitfall: Patients often try to rapidly warm cold extremities (e.g., placing hands directly on a heater), which paradoxically worsens symptoms through vasospasm. Emphasize gradual, gentle rewarming. 4
Pharmacologic Treatment Options
First-Line: Calcium Channel Blockers
Nifedipine is the most studied and recommended pharmacologic treatment:
- Nifedipine produces vasodilation and has been demonstrated to reduce pain, facilitate healing, and prevent new lesions 3
- A systematic review found moderate evidence supporting nifedipine for severe or refractory idiopathic chilblains 2
- However, effectiveness is not confirmed by all studies—the evidence remains mixed 1
- Typical dosing: 20 mg three times daily (though specific dosing should follow standard nifedipine protocols)
Important caveat: While nifedipine is the most evaluated treatment, its inconsistent efficacy across studies means some patients may not respond. 1, 2
Second-Line Options
Pentoxifylline has moderate evidence for severe or refractory cases 2, though fewer studies support its use compared to nifedipine 1
Topical corticosteroids (particularly betamethasone) are commonly used in clinical practice, but their effectiveness has not been confirmed by randomized clinical trials 1
Limited Evidence Treatments
The following have shown benefit only in small numbers of patients:
Acupuncture appears to provide some benefit based on limited data 1
Clinical Evaluation
Screen for secondary causes before diagnosing idiopathic chilblains:
- Check for systemic symptoms and underlying autoimmune disease 1
- Laboratory evaluation should include antinuclear antibody profile to exclude systemic lupus erythematosus 3
- Screen for cryoproteins and antiphospholipid antibodies in appropriate clinical contexts 3
- Consider anorexia nervosa in thin adolescents, as low BMI (<25th percentile) is a risk factor 3, 5
Skin biopsy can be useful in dubious cases, showing dermal edema and inflammatory infiltrate particularly around eccrine glands 1
Natural History and Prognosis
- Acute pernio typically develops 12-24 hours after cold exposure 3
- Lesions usually begin in fall/winter and spontaneously resolve in spring or early summer 1, 3
- Most patients improve with warmer weather or cold protection advice alone 5
- The prognosis for properly treated pernio is excellent 3
Reassurance is important: Chilblains are almost always benign, patients are systemically well, and most need only symptomatic treatment. Prompt recognition avoids excessive investigation and anxiety. 5
Treatment Algorithm
- All patients: Cold avoidance, protective clothing, gradual rewarming, smoking cessation
- Mild cases: Observation with non-pharmacologic measures; consider topical corticosteroids (though unproven)
- Moderate-to-severe or refractory cases: Add oral nifedipine
- Non-responders to nifedipine: Consider pentoxifylline as alternative
- Persistent cases: Re-evaluate for secondary causes; consider referral to rheumatology or dermatology
Special consideration for adolescents: Thin body habitus increases risk—counsel on adequate clothing and avoiding fashion choices that expose extremities to cold (e.g., wearing sandals in winter). 3, 5